Nasdaq, Inc. (NDAQ) Stock Forecast
Data as of Oct 31, 2026Financial Services · Current price $106.12 (+0.49%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 25, 2026 | Patrick O\'Shaughnessy | Raymond James | $109.00 | +2.7% |
| Jan 30, 2026 | Michael Cyprys | Morgan Stanley | $116.00 | +9.3% |
| Jan 12, 2026 | Alex Kramm | UBS | $120.00 | +13.1% |
| Oct 22, 2025 | Benjamin Budish | Barclays | $109.00 | +2.7% |
| Oct 13, 2025 | Patrick O'Shaughnessy | Raymond James | $100.00 | -5.8% |
| Oct 8, 2025 | Benjamin Budish | Barclays | $108.00 | +1.8% |
| Jul 9, 2025 | Patrick O'Shaughnessy | Raymond James | $96.00 | -9.5% |
| Jun 17, 2025 | Owen Lau | Oppenheimer | $96.00 | -9.5% |
| Jan 9, 2025 | Patrick O'Shaughnessy | Raymond James | $84.00 | -20.8% |
| Oct 14, 2024 | Patrick O'Shaughnessy | Raymond James | $82.00 | -22.7% |
| Sep 26, 2024 | Ashish Sabadra | RBC Capital | $88.00 | -17.1% |
| Sep 4, 2024 | Joseph Moore | Morgan Stanley | $55.00 | -48.2% |
| Sep 4, 2024 | Craig Siegenthaler | Bank of America Securities | $90.00 | -15.2% |
| Jul 30, 2024 | Owen Lau | Oppenheimer | $78.00 | -26.5% |
| May 14, 2024 | Kevin Heal | Argus Research | $66.00 | -37.8% |
| Apr 12, 2024 | Owen Lau | Oppenheimer | $72.00 | -32.2% |
| Apr 11, 2024 | Benjamin Budish | Barclays | $76.00 | -28.4% |
| Apr 9, 2024 | Michael Cyprys | Morgan Stanley | $80.00 | -24.6% |
| Apr 5, 2024 | Brian Bedell | Deutsche Bank | $60.00 | -43.5% |
| Mar 26, 2024 | Alexander Blostein | Goldman Sachs | $73.00 | -31.2% |
Top Analysts Covering NDAQ
NDAQ vs Sector & Market
| Metric | NDAQ | Financial Services Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.51 | 2.41 |
| Analyst Count | 17 | 9 | 19 |
| Target Upside | +6.1% | +132.9% | +21.5% |
| P/E Ratio | 31.96 | -4.36 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.54B | $5.74B | $5.85B | 8 |
| 2027-03-31 | $1.48B | $1.50B | $1.52B | 4 |
| 2027-06-30 | $1.52B | $1.54B | $1.56B | 4 |
| 2027-09-30 | $1.52B | $1.54B | $1.56B | 5 |
| 2027-12-31 | $1.59B | $1.62B | $1.64B | 4 |
| 2028-03-31 | $1.60B | $1.63B | $1.65B | 3 |
| 2028-06-30 | $1.63B | $1.66B | $1.68B | 3 |
| 2028-09-30 | $1.62B | $1.65B | $1.66B | 5 |
| 2028-12-31 | $1.71B | $1.74B | $1.76B | 3 |
| 2029-12-31 | $6.90B | $7.11B | $7.23B | 3 |
| 2030-12-31 | $7.17B | $7.38B | $7.51B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.06 | $3.92 | $4.11 | 11 |
| 2027-03-31 | $1.04 | $1.06 | $1.07 | 5 |
| 2027-06-30 | $1.06 | $1.08 | $1.10 | 5 |
| 2027-09-30 | $1.08 | $1.10 | $1.12 | 5 |
| 2027-12-31 | $1.15 | $1.17 | $1.19 | 5 |
| 2028-03-31 | $1.18 | $1.20 | $1.22 | 6 |
| 2028-06-30 | $1.21 | $1.24 | $1.26 | 6 |
| 2028-09-30 | $1.25 | $1.28 | $1.30 | 7 |
| 2028-12-31 | $1.33 | $1.35 | $1.37 | 9 |
| 2029-12-31 | $5.30 | $5.51 | $5.63 | 2 |
| 2030-12-31 | $5.82 | $6.05 | $6.18 | 2 |
Frequently Asked Questions
What is the analyst consensus for NDAQ?
The consensus among 17 analysts covering Nasdaq, Inc. (NDAQ) is Buy with an average price target of $113.40.
What is the highest price target for NDAQ?
The highest price target for NDAQ is $120.00, set by Alex Kramm at UBS on 2026-01-12.
What is the lowest price target for NDAQ?
The lowest price target for NDAQ is $55.00, set by Joseph Moore at Morgan Stanley on 2024-09-04.
How many analysts cover NDAQ?
17 analysts have issued ratings for Nasdaq, Inc. in the past 12 months.
Is NDAQ a buy or sell right now?
Based on 17 analyst ratings, NDAQ has a consensus rating of Buy (2.12/5) with a +6.1% upside to the consensus target of $113.40.
What are the earnings estimates for NDAQ?
Analysts estimate NDAQ will report EPS of $3.92 for the period ending 2026-12-31, with revenue estimated at $5.74B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.